In recent years, commercial and clinical efforts to use blood components, whether autologous or allogeneic, to develop and deliver novel drug therapies have grown substantially. The Red Cross is playing a key role in this arena, providing cell collection support and contract manufacturing services to leading biotechnology companies.

Red Cross staff in our two clean rooms in Philadelphia perform contract manufacturing to the exact specifications provided by our biotechnology clients, utilizing blood components collected by the Red Cross or third parties.